Belrestotug

iTeos Therapeutics and GlaxoSmithKline have discontinued development of their TIGIT inhibitor belrestotug after Phase II clinical trials failed to meet efficacy endpoints in non-small cell lung cancer and head and neck squamous cell carcinoma.

GSK and iTeos Therapeutics have discontinued development of belrestotug, their TIGIT-targeting immunotherapy, after it failed to significantly delay tumor progression in non-small cell lung cancer patients.

Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions.

iTeos Therapeutics raises $120 million in direct offering led by RA Capital Management and Boxer Capital, extending cash runway through 2027 for advancing belrestotug development.

Interim Phase 2 GALAXIES Lung-201 study demonstrates superior objective response rate for belrestotug-dostarlimab combination compared to dostarlimab monotherapy in PD-L1-high non-small cell lung cancer patients.